Abstracts tagged "Inflammation"

Abstract Number: 24 • 2017 ACR/ARHP Annual Meeting
Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis
Priti Prasad¹, Michael Fishbein², Rohan Sharma³, Ramesh Halder⁴, Isela Valera¹ and Ram R. Singh⁵, ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ³Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los angeles, CA, ⁴Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ⁵Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Lung is involved in up to 50% patients with SLE. Among manifestations of pulmonary lupus, pneumonitis, vasculitis and diffuse pulmonary hemorrhage (DPH) carry a…
Abstract Number: 976 • 2017 ACR/ARHP Annual Meeting
Cannabinoid Receptor 2 Agonist (JWH-015) Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts
Sabrina Fechtner and Salahuddin Ahmed, Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by activated synovial fibroblasts in which pro-inflammatory cytokine interleukin-1β (IL-1β) mediates inflammation. The endocannabinoid system…
Abstract Number: 1790 • 2017 ACR/ARHP Annual Meeting
Sphingosine -1 Phosphate Receptor-1-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE
Nathalie Burg¹, Steven Swendeman², Stefan Worgall³, Timothy Hla² and Jane E. Salmon¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Boston Children's Hospital, Boston, MA, ³Pediatrics/ Pulmonary, Weill Cornell Medical Center, New York, NY
Background/Purpose: Sphingosine 1-phosphate (S1P), a bioactive lysophospholipid, is important for vascular homeostasis via signaling through S1P receptors. HDL-bound apolipoprotein M (ApoM) is a physiological S1P…
Abstract Number: 73 • 2017 ACR/ARHP Annual Meeting
Regulation of Th17 Cell Responses By IL-25
Sophie Archer, Ash Maroof, Meryn Griffiths and Stevan Shaw, UCB Pharma, Slough, United Kingdom
Background/Purpose: IL-17A is a Th17 proinflammatory cytokine that contributes to the pathophysiology of several immune-mediated inflammatory diseases including PsA; while previously underestimated, there is increasing…
Abstract Number: 1071 • 2017 ACR/ARHP Annual Meeting
Increased Susceptibility of SLE-Prone Mice to Pulmonary Haemophilus Influenzae Infection Was Attributed to Dysfunctions of Innate Immune Responses
Wenchao Li and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Aside from the disease itself, infections represent the major cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. Although the daily usage…
Abstract Number: 1863 • 2017 ACR/ARHP Annual Meeting
Inflammatory Dietary Pattern and Risk of Developing Rheumatoid Arthritis in Women
Bing Lu¹, Jeffrey A. Sparks¹, Susan Malspeis¹, Medha Barbhaiya¹, Sara K. Tedeschi², Karen H. Costenbader³ and Elizabeth Karlson³, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy,, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The preclinical period of rheumatoid arthritis (RA) is characterized by elevated inflammatory biomarkers but it is unclear whether inflammatory diet may contribute to RA…
Abstract Number: 82 • 2017 ACR/ARHP Annual Meeting
CKD-506, a Novel Inhibitor of Histone Deacetylase 6 (HDAC6) Has a Therapeutic Potential in Rheumatoid Arthritis and Inflammatory Bowel Disease
Jieun Shin¹, Nina Ha¹, Daekwon Bae¹, Dong-Hyeon Suh¹, Yu Jin Jang², Sehui Shon³, Ji-yeon Baek¹, Jae Hyun Jun¹, Yong Jae Lee¹, Changsik Lee¹, Sei-Hwan Kim¹, Hosung Yu¹, Young Il Choi¹, Keun Ho Ryu¹, Soung-Min Lee⁴, Yeong Wook Song², Su K Seo⁴ and Seong Kon Kim¹, ¹Research Institute of Chong Kun Dang Pharmaceutical Corporation, Yongin, Korea, Republic of (South), ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁴Department of Microbiology and Immunology, Inje University College of Medicine, Busan, Korea, Republic of (South)
Background/Purpose: Autoimmune disease such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) is a chronic inflammatory disorder, significantly limiting quality of life. Even though…
Abstract Number: 1101 • 2017 ACR/ARHP Annual Meeting
Systematic Physician Assessment Beyond Inflammation in Routine Rheumatology Care Using Visual Analog Scale Scores for Inflammation, Damage, and Distress to Document Patient Status and Support Clinical Decisions: Analysis of Inter-Rater Reliability
Shakeel M. Jamal¹, Theodore Pincus², Isabel Castrejón², Jacquelin R. Chua¹, Aman Kugasia¹, Juan Schmukler¹, Stacy Weinberg¹ and Joel A. Block³, ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: A physician global estimate of patient status (DOCGL) on a 0-10 visual analog scales (VAS) is as effective as any rheumatoid arthritis (RA) Core…
Abstract Number: 1928 • 2017 ACR/ARHP Annual Meeting
Fibroblast-like Synovial Cell Production of ED-a Fibronectin Contributes to Inflammation in Osteoarthritis
Tue Wenzel Kragstrup^1,2,3, Dong Hyun Sohn⁴, Christin Lepus³, Kazuhiro Onuma⁵, Qian Wang³, William H. Robinson³ and Jeremy Sokolove³, ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁴Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South), ⁵VA Palo Alto Healthcare System and Stanford University, Stanford, CA
Background/Purpose: The pathophysiology of osteoarthritis (OA) involves wear and tear, and a state of low-grade inflammation. Wear and tear leads to tissue degradation followed by…
Abstract Number: 86 • 2017 ACR/ARHP Annual Meeting
Regulation of Interleukin-1β Signaling By Inhibition of O-Glc-Nacase in Rheumatoid Arthritis Synovial Fibroblasts
Mahamudul Haque¹, Anil Singh², Kelly Kopczynski¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: O-GlcNAcylation is an important post-translational modification of nuclear and cytosolic proteins involved in the cytokine signaling networks. Studies show both pro- and anti-inflammatory roles…
Abstract Number: 1203 • 2017 ACR/ARHP Annual Meeting
Differences in Serum Protein Biomarkers between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients
Sandi L Navarro¹, Marta Herrero², Helena Martinez², Jon Ladd¹, Yuzheng Zhang¹, Edward Lo¹, David Shelley¹, Timothy W Randolph¹, Yvonne Schwarz¹, Johanna W Lampe¹ and Paul D Lampe¹, ¹Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain
Background/Purpose: Non-steroidal anti-inflammatory drugs, e.g., celecoxib, are commonly used for inflammatory conditions, including osteoarthritis (OA), but are associated with adverse effects. Combined glucosamine hydrochloride plus…
Abstract Number: 1949 • 2017 ACR/ARHP Annual Meeting
Anti-Inflammatory Effects of Standardized Platelet-Rich Plasma Releasates in Knee and Hip OA Chondrocytes
Lucia Gato-Calvo¹, Ángela Vela-Anero², Elena F. Burguera¹ and Francisco J Blanco³, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade de A Coruña (UDC), A Coruña, Spain, ²Cell Therapy and Regenerative Medicine Group, Department of Medicine, University of A Coruña, A Coruña, Spain, ³Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Spain
Background/Purpose : There is a need to standardize platelet-rich plasma (PRP)-derived products and their dosage to evaluate efficacy for each intended indication. Our purpose here…
Abstract Number: 165 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Risk Polymorphisms in CCR6, SNP and Estrogen-Dependent Response to Immune Mediator Gene Expression, and NF-κb Transcriptional Activity: Crosstalk between the Immune and Endocrine Systems
Ming-Fen Ho¹, Tim Bongartz², James N. Ingle³, Liewei Wang¹ and Richard M. Weinshilboum¹, ¹Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, ²Emergency Medicine, Vanderbilt University, Nashville, TN, ³Department of Medical Oncology, Mayo Clinic, Rochester, MN
Background/Purpose: The rheumatoid arthritis (RA) risk locus CCR6 rs3093024 SNP is associated with increased risk of RA in a sex-specific pattern in Asian populations. Specifically,…
Abstract Number: 1205 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Low-Dose Radiation Therapy on Symptoms in Knee Osteoarthritis: First Results of a Triple Blinded, Randomized Controlled Trial
E.A.M. Mahler¹, M.J.M Minten¹, M.M. Leseman-Hoogenboom², P.M.P. Poortmans², S.S. Boks³, J.W.J. Bijlsma⁴, F.H.J. van den Hoogen^1,5, A.A. Den Broeder^1,5 and C.H.M. van den Ende^1,5, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Radiation Therapy, Radboud university medical centre, Nijmegen, Netherlands, ³Radiology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Radboud university medical centre, Nijmegen, Netherlands
Background/Purpose: Previous research in animal osteoarthritis (OA) has shown that low-dose radiation therapy (LD-RT) exerts anti-inflammatory effects, but a systematic review concluded that the evidence…
Abstract Number: 2016 • 2017 ACR/ARHP Annual Meeting
Favourable Changes in Power Doppler Scores in the Feet over 1-Year in an Early Rheumatoid Arthritis Cohort: The Role of Rheumatoid Factor and Anti–Citrullinated Protein Antibody
Karen A. Beattie¹, Hanyan Zou², George Ioannidis³ and Maggie Larche¹, ¹Medicine, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose : MTP joints are seldom examined in routine clinical visits. As such, it is important to understand how the standard treatment of patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].